Gongwin Biopharm Holdings Co (ROCO:6617) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6617 Gongwin Biopharm Holdings Co Ltd ROCO:6617
70 GF Score
Price NT$100.00
GF Value NT$151.75
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Gongwin Biopharm Holdings Co FFO?

FFO (Funds from operations) only applies to REITs.

ROCO:6617
70GF Score
Gongwin Biopharm Holdings Co Ltd ROCO:6617
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gongwin Biopharm Holdings Co (ROCO:6617) Overvalued in 2026?

Based on GuruFocus' analysis, Gongwin Biopharm Holdings Co stock appears to be undervalued. The current stock price of NT$100.00 is trading 34.1% below its estimated GF Value™ of NT$151.75. GuruFocus considers Gongwin Biopharm Holdings Co to be Significantly Undervalued.

Key valuation signals for ROCO:6617:

  • FFO:
  • GF Value™: NT$151.75 vs. price of NT$100.00 (34.1% below fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6617 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gongwin Biopharm Holdings Co Business Description

Address 3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
70GF Score

Get the complete analysis for ROCO:6617

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$100.00
Price
NT$151.75
GF Value